Working… Menu

Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), in Renal Transplant Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00403416
Recruitment Status : Completed
First Posted : November 23, 2006
Last Update Posted : May 18, 2017
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
This study will evaluate the efficacy and safety of AEB071 in preventing acute rejections after kidney transplantation, when combined with tacrolimus for the first 3 months and with myfortic thereafter.

Condition or disease Intervention/treatment Phase
Kidney Transplantation Drug: AEB071 Drug: Mycophenolic Acid Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 215 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: 12-month Open Label, Randomized, Multicenter Study Evaluating Efficacy, Safety and Tolerability of Oral AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), vs. Mycophenolic Acid Plus Tacrolimus in de Novo Renal Transplant Recipients
Study Start Date : October 2006
Actual Primary Completion Date : May 2008
Actual Study Completion Date : May 2008

Arm Intervention/treatment
Active Comparator: Mycophenolic Acid / tacrolimus Drug: Mycophenolic Acid
Experimental: AEB071 / tacrolimus arm 1 Drug: AEB071
Experimental: AEB071 / tacrolimus arm 2 Drug: AEB071

Primary Outcome Measures :
  1. Primary efficacy failure, defined as a composite efficacy endpoint of treated biopsy-proven acute rejection (BPAR), graft loss, death or loss to follow-up [ Time Frame: at 6 months ]

Secondary Outcome Measures :
  1. Renal function post-transplant Modification of diet in renal disease (MDRD) formula for Glomerular Filtration Rate) [ Time Frame: at 6 months ]
  2. Primary efficacy failure, defined as a composite efficacy endpoint of treated BPAR, graft loss, death or loss to follow-up [ Time Frame: at 3 and 12 months ]
  3. Various efficacy endpoints, using treated BPAR, treated acute rejection (AR), death, graft loss, loss to follow-up and combinations thereof. [ Time Frame: at Month 3, 6 and 12 ]
  4. Changes in renal function (GFR) after replacing tacrolimus by myfortic in the AEB071 treatment arms [ Time Frame: from Month 3 to Month 6 ]
  5. Safety and tolerability [ Time Frame: at 3, 6 and 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

  • Male and female patients of any race 18 years or older
  • Adult recipients of a kidney transplant from a deceased or from a living donor
  • Recipients of a functioning Kidney:. Graft must be functional no later than 36h after transplantation.

Exclusion criteria

  • Need for medication prohibited by the protocol
  • Patients or donors infected with hepatitis B or C, or with HIV.
  • Patients with a history of cancer
  • Patients with severe systemic infections Patients with heart diseases (own or family history) which are associated with an increased risk for arrhythmias.

Other protocol-defined inclusion/exclusion criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00403416

Layout table for location information
United States, California
University of California, San Francisco
San Francisco, California, United States, 94143-0780
United States, Ohio
University Hospitals of Cleveland
Cleveland, Ohio, United States, 44106-5048
United States, Wisconsin
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States, 53792-7375
QE II Health Sciences Center
Halifax, Canada, B3H 1V7
Hopital Kremlin Bicetre
Le Kremlin Bicetre, France, 94270
Hopital Hotel Dieu
Nantes, France, 44035
Hopital Necker
Paris, France, 75015
CHU de Rangueil
Toulouse, France, 31403
Universitaetsklinik Charite
Berlin, Germany, 10117
Klinikum der Humboldt Universitat Charite
Berlin, Germany, 13353
Universitaetsklinikum Essen
Essen, Germany, 45122
Medizinische Hochschule Hannover
Hannover, Germany, 30625
Univ. - Klinikum Heidelberg
Heidelberg, Germany, 69120
Staedt. Krankenhaus Koeln-Merheim
Koeln, Germany, 51109
Az. Osp. Di Bologna Polici. S. Orsola - Malpighi
Bologna, Italy, 40138
Azienda Opedaliera Careggi - Universita degli Studi
Firenze, Italy, 50134
Azienda Ospedaliera di Padova - Universita degli Studi
Padova, Italy, 35128
Ciutat Santitaria I Univessitaria de Bellvitge
Hospitalet de Llobregat, Spain, 08907
Hospital 12 de Octubre
Madrid, Spain, 28041
Complejo Hospitalario Carlos Haya
Malaga, Spain, 28041
Hospital Doctor Peset
Valencia, Spain, 46017
Universitatsspital Basel
Basel, Switzerland, 4031
Inselspital Bern
Bern, Switzerland, 3010
Universitätsspital Zürich
Zürich, Switzerland, 8091
United Kingdom
University Hospital of Wales
Cardiff, United Kingdom, CF14 4XW
Western Infirmary
Glasgow, United Kingdom, G11 6NT
Saint George's University of London
London, United Kingdom
Manchester Royal Infirmary
Manchester, United Kingdom
Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Additional Information:
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals Identifier: NCT00403416     History of Changes
Other Study ID Numbers: CAEB071A2203
First Posted: November 23, 2006    Key Record Dates
Last Update Posted: May 18, 2017
Last Verified: May 2017
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Mycophenolic acid
Kidney function
Additional relevant MeSH terms:
Layout table for MeSH terms
Mycophenolic Acid
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antibiotics, Antineoplastic
Antineoplastic Agents
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents